On Mar 5, 2014, Zacks Investment Research downgraded
Mindray Medical International Ltd
) by a notch to a Zacks Rank #2 (Buy).
Why the Downgrade?
Mindray Medical International Limited
), the Chinese medical device maker, reported
stronger-than-expected fourth-quarter 2013 results on March 3.
However, increasing leverage ratio, decreasing gross and
operating margins, as well as a weak domestic market disappointed
investors as share price dropped 8.3% since the earnings release.
Mindray's net revenues grew 16.5% to $368.4 million, surpassing
the Zacks Consensus Estimate of $348 million. While international
revenues grew 23.8%, revenues from China grew at a slower pace of
8.3% due to delays in purchasing activities.
Mindray expects Western Europe and certain other emerging markets
to continue to perform well and contribute to top-line growth in
2014. However, a sluggish market in China remains a matter of
concern for the company's earnings going forward.
As of Dec 31, 2013, Mindray's long-term debt-to-equity ratio was
0.15 compared with 0.04 as of Dec 31, 2012. The stark increase in
this ratio within a year, leading to a 55.0% increase in interest
expense year over year, is likely to disappoint investors.
Adjusted gross profit rose 12.6% to $207.8 million but gross
margin declined 200 basis points (bps) to 56.4% in the quarter
due to increased cost of revenues. Adjusted operating profit went
up 14.1% to $72.0 million but operating margin dipped 50 bps to
19.5% due to increased selling, general and administrative
expenses and higher research and development expenses.
Subsequently, the company has seen a negative trend in earnings
estimate revisions in the past 7 days. For the current quarter,
one estimate moved south in the past 7 days, with no upward
revision in the same time frame. This trend has caused the
consensus estimate to move down by 2 cents to its current level
of 38 cents over a week.
Other Stocks to Consider
Other stocks in the medical instruments industry with a favorable
Zacks Ranks include
Natus Medical Inc
Syneron Med Ltd.
). All the three stocks sport a Zacks Rank #1 (Strong Buy).
NATUS MEDICAL (BABY): Free Stock Analysis
CYNOSURE INC-A (CYNO): Free Stock Analysis
SYNERON MED LTD (ELOS): Free Stock Analysis
MINDRAY MEDICAL (MR): Free Stock Analysis
To read this article on Zacks.com click here.